Literature DB >> 27426025

PD-1/PD-L1 blockade in renal cell cancer.

Kathryn E Beckermann1, Douglas B Johnson1, Jeffrey A Sosman2.   

Abstract

INTRODUCTION: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.

Entities:  

Keywords:  PD-1; PD-L1; Renal cell; atezolizumab; nivolumab; pembrolizumab

Mesh：

Substances：

Year:  2016        PMID： 27426025      PMCID： PMC5555220          DOI： 10.1080/1744666X.2016.1214575

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


  49 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.

Authors:  Bradley C Leibovich; Christine M Lohse; Paul L Crispen; Stephen A Boorjian; R Houston Thompson; Michael L Blute; John C Cheville
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

Review 3.  Potential of new therapies like anti-PD1 in kidney cancer.

Authors:  Anasuya Gunturi; David F McDermott
Journal:  Curr Treat Options Oncol       Date:  2014-03

4.  Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Authors:  Christel Devaud; Jennifer A Westwood; Michele Wl Teng; Liza B John; Carmen Sm Yong; Connie Pm Duong; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

5.  Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

Authors:  David F McDermott; Charles G Drake; Mario Sznol; Toni K Choueiri; John D Powderly; David C Smith; Julie R Brahmer; Richard D Carvajal; Hans J Hammers; Igor Puzanov; F Stephen Hodi; Harriet M Kluger; Suzanne L Topalian; Drew M Pardoll; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Dan McDonald; Vindira Sankar; Jeffrey A Sosman; Michael B Atkins
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Phase I/II study of ipilimumab for patients with metastatic melanoma.

Authors:  Jeffrey S Weber; Steven O'Day; Walter Urba; John Powderly; Geoff Nichol; Michael Yellin; Jolie Snively; Evan Hersh
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

9.  Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.

Authors:  Yosra Messai; Sophie Gad; Muhammad Zaeem Noman; Gwenael Le Teuff; Sophie Couve; Bassam Janji; Solenne Florence Kammerer; Nathalie Rioux-Leclerc; Meriem Hasmim; Sophie Ferlicot; Véronique Baud; Arnaud Mejean; David Robert Mole; Stéphane Richard; Alexander M M Eggermont; Laurence Albiges; Fathia Mami-Chouaib; Bernard Escudier; Salem Chouaib
Journal:  Eur Urol       Date:  2015-12-23       Impact factor: 20.096

Review 10.  The molecular biology of renal cell carcinoma.

Authors:  Stephen M Keefe; Katherine L Nathanson; W Kimryn Rathmell
Journal:  Semin Oncol       Date:  2013-08       Impact factor: 4.929
View more
  10 in total

1.  A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.

Authors:  Xiaopei Cui; Huifeng Jia; Hong Xin; Lei Zhang; Shi Chen; Simin Xia; Xue Li; Wei Xu; Xiaofang Chen; Yujie Feng; Xiaoyue Wei; Haijia Yu; Yanting Wang; Yifan Zhan; Xiangyang Zhu; Xuemei Zhang
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

Review 2.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

Review 3.  Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.

Authors:  Vyshak Alva Venur; Monika Joshi; Kenneth G Nepple; Yousef Zakharia
Journal:  Drug Des Devel Ther       Date:  2017-04-11       Impact factor: 4.162

Review 4.  Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Authors:  Christiane Thallinger; Thorsten Füreder; Matthias Preusser; Gerwin Heller; Leonhard Müllauer; Christoph Höller; Helmut Prosch; Natalija Frank; Rafal Swierzewski; Walter Berger; Ulrich Jäger; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2017-11-02       Impact factor: 1.704

5.  Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors.

Authors:  Jia-Xi Yao; Xiang Chen; Wei Xi; Yan-Jun Zhu; Hang Wang; Xiao-Yi Hu; Jian-Ming Guo
Journal:  J Cancer       Date:  2018-10-18       Impact factor: 4.207

Review 6.  Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases.

Authors:  Xin Cai; Huajie Zhan; Yuguang Ye; Jinjin Yang; Minghui Zhang; Jing Li; Yuan Zhuang
Journal:  Front Genet       Date:  2021-11-30       Impact factor: 4.599

7.  Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.

Authors:  Chunyan Yue; Yubo Jiang; Ping Li; Yuehua Wang; Jian Xue; Nannan Li; Da Li; Ruina Wang; Yongjun Dang; Zhiyuan Hu; Yanlian Yang; Jianming Xu
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

8.  A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity.

Authors:  Snigdha Majumder; Rakshit Shah; Jisha Elias; Yogesh Mistry; Karunakaran Coral; Priyanka Shah; Anand Kumar Maurya; Bharti Mittal; Jason K D'Silva; Sakthivel Murugan; Lakshmi Mahadevan; Rekha Sathian; V L Ramprasad; Papia Chakraborty; Ravi Gupta; Amitabha Chaudhuri; Arati Khanna-Gupta
Journal:  PLoS One       Date:  2018-09-26       Impact factor: 3.240

9.  Identifying hub genes of clear cell renal cell carcinoma associated with the proportion of regulatory T cells by weighted gene co-expression network analysis.

Authors:  Ye-Hui Chen; Shao-Hao Chen; Jian Hou; Zhi-Bin Ke; Yu-Peng Wu; Ting-Ting Lin; Yong Wei; Xue-Yi Xue; Qing-Shui Zheng; Jin-Bei Huang; Ning Xu
Journal:  Aging (Albany NY)       Date:  2019-10-31       Impact factor: 5.682

10.  CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation.

Authors:  Kathryn E Beckermann; Rachel Hongo; Xiang Ye; Kirsten Young; Katie Carbonell; Diana C Contreras Healey; Peter J Siska; Sierra Barone; Caroline E Roe; Christof C Smith; Benjamin G Vincent; Frank M Mason; Jonathan M Irish; W Kimryn Rathmell; Jeffrey C Rathmell
Journal:  JCI Insight       Date:  2020-08-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.